Lynparza received FDA approval to treat ovarian cancer
-
Last Update: 2021-02-17
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
AstraZeneca and MSD announced that Lynparza has been approved by the FDA for first-line maintenance treatment for advanced ovarian cancer with BRCA mutations, further expanding the use of the drug.decision, based on Phase III data, Lynparza reduced the risk of disease progression or death in this environment by 70 percent compared to placebo.The SOLO-1 trial also found that 60 percent of patients treated with Lynparza had no progress within three years, up from 27 percent in the placebo group."SOLO-1 is really a landmark gynecological cancer trial," said Kathleen Moore, co-lead researcher of the SOLO-1 trial and associate director of clinical research at the University of Oklahoma's Stephenson Cancer Center. The ability to provide eligible patients with this important first-line maintenance treatment option may slow or even halt the natural process of disease progression. InLynparza, AstraZeneca and MSD are exploring other trials of advanced ovarian cancer, including the ongoing GINECO/ENGOTov25 Phase III trial, PAOLA-1.in the trial, they are testing the effectiveness of Lynparza and (Avastin) Beva monoantigen as a maintenance treatment for newly diagnosed patients with advanced ovarian cancer, regardless of their BRCA status, and are expected to produce results in the second half of 2019.Lynparza has become the first PARP inhibitor to be approved for first-line maintenance therapy, pushing it to the forefront of its competitors. (Compiled by this web)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
